MS decreases the larger amplitude distribution in adult rats. by Jesús David Ayala-Rodríguez (17364296)

Data_Sheet_1_Immune and Neuroendocrine Trait and State Markers in Psychotic Illness: Decreased Kynurenines Marking Psychotic Exacerbations.docx by Livia De Picker (8319105)

“…</p><p>Conclusion: The acute psychotic state is marked by state-specific increases of immune markers and decreases in peripheral IDO pathway markers. …”

Contact structure can have a significant impact on the population immunity threshold. by Simon Bauer (11378195)

Deletion of <i>sagA</i> alone results in a decrease in nasopharyngeal infection. by Blake A. Shannon (14197601)

(A) Auxiliary marking points to ensure complete and accurate seating of the prosthesis. by Long Li (6555)

Subjects:

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

Data. by Su Hwan Park (15158181)

“…Participants in the progression group were younger (60.7 vs. 65.7 years, P = 0.015) and showed a larger BCVA change (0.20 vs. 0.04, P < 0.001) and greater ERM area decrease (34.2% vs. 11.7%, P < 0.001) during the follow-up period. …”

A noxious temperature decrease without a prior increase produces a subtly larger decrease in pain intensity. by Benedict J. Alter (9745466)

S1 Data - by Xiaohua Zhuang (11890694)

Subjects:

PD-1 deficiency does not significantly impact the pathogen load and pathology following <i>S</i>. <i>japonicum</i> infection. by Liaoxun Lu (179293)

Subjects:

Significantly Enriched Pathways. by Jiyong Zhang (2498740)

Subjects:

Larger example of stimuli with cue relevant for Task 3. by Marcel F. Hinss (14675457)

The level of miRNA 221 in the myocardium of MIRI mice was decreased. by Hongyu Li (1332669)

Subjects:

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Study CONSORT diagram. by Benjamin R. Lewis (22279166)

Subjects: